ADAM10 and Alzheimer disease: Taken together, our current study and the previous studies demonstrate that a substrate‐selective activation of ADAM10 is in principle feasible and suggests that additional ADAM10 activators beyond acitretin may be identified in drug development for a future substrate‐selective ADAM10 activation in AD.